BioCentury | Mar 17, 2020
Product Development

March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

...factor pathway inhibitor Sandi Wong, Assistant Editor and Elizabeth S. Eaton, Staff Writer Empliciti, elotuzumab (HuLuc63, BMS-901608, PDL 063) Bavencio...
BioCentury | Mar 14, 2020
Emerging Company Profile

Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

...added that in mice modeling myeloma, treatment with the cells plus Darzalex daratumumab or Empliciti elotuzumab...
BioCentury | Aug 27, 2019
Company News

Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano

...Empliciti combo approval in Europe Bristol-Myers Squibb Co. (NYSE:BMY) said the European Commission approved Empliciti elotuzumab...
...19; IL-7 - Interleukin-7; SLAMF7 (CS1) - SLAM family member 7 BioCentury Staff Empliciti, elotuzumab (HuLuc63, BMS-901608, PDL 063) inebilizumab...
BioCentury | Jun 14, 2019
Clinical News

June 14 Clinical Quick Takes: Chi-Med, BeiGene, UCB, Global Blood and more

...in The New England Journal of Medicine and presented the data at the EHA meeting. Empliciti...
...the Phase II ELOQUENT-3 trial to treat relapsed or refractory multiple myeloma showing that Empliciti elotuzumab...
...IL-23 subunit α; SLAMF7 (CS1) - SLAM family member 7 BioCentury Staff bimekizumab (UCB4940) Empliciti, elotuzumab (HuLuc63, BMS-901608, PDL 063) REGN1979 sulfatinib...
BioCentury | Nov 9, 2018
Clinical News

FDA approves Empliciti plus pomalidomide and dexamethasone for MM

...Bristol-Myers Squibb Co. (NYSE:BMY) said FDA approved an sBLA for Empliciti elotuzumab in combination with pomalidomide...
...vs. 4.7 months, p=0.0078) (see "BMS's Empliciti Meets in Phase II to Treat MM" ). Empliciti...
...Squibb Co. (NYSE:BMY), New York, N.Y. Product: Empliciti elotuzumab Business: Cancer Jennie Walters Empliciti, elotuzumab (HuLuc63, BMS-901608, PDL 063) AbbVie...
BioCentury | Jul 13, 2018
Clinical News

BMS's Empliciti meets in Phase II for MM

...II ELOQUENT-3 trial in 117 patients with relapsed or refractory multiple myeloma showing that Empliciti elotuzumab...
...AbbVie Inc. (NYSE:ABBV), North Chicago, Ill. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Empliciti elotuzumab...
...NA Alicia Parker Empliciti (Brand), HuLuc63 (Compound #), BMS-901608 (Compound #), PDL 063 (Former compound #), elotuzumab (Generic), Empliciti...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...approval 9-mo sales in 2017 (millions) AbbVie Inc. (NYSE:ABBV) / Bristol-Myers Squibb Co. (NYSE:BMY) Empliciti elotuzumab...
BioCentury | Dec 15, 2017
Clinical News

Holds lifted for two Opdivo MM trials

...is evaluating Opdivo and Darzalex daratumumab with or without an IMiD. CA204142 is evaluating Empliciti elotuzumab...
BioCentury | Jul 15, 2017
Product Development

Excessive immunity?

...trial includes an exploratory arm evaluating the combination of Opdivo, Pomalyst, dexamethasone and BMS’s Empliciti elotuzumab...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...U.S. $32 (North American sales only) Bristol-Myers Squibb Co. (NYSE:BMY) / AbbVie Inc. (NYSE:ABBV) Empliciti elotuzumab...
...Intelligence Company Product Indication 2016 approval AbbVie Inc. (NYSE:ABBV) / Bristol-Myers Squibb Co. (NYSE:BMY) Empliciti elotuzumab...
Items per page:
1 - 10 of 64